A genetics-led approach defines the drug target landscape of 30 immune-related traits
Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection1. Drug targets with genetic support are more likely to be therapeutically valid2,3, but the translational use of genome-scale data such as from genome-wide associat...
Príomhchruthaitheoirí: | Fang, H, De Wolf, H, Knezevic, B, Burnham, K, Osgood, J, Sanniti, A, Lledó Lara, A, Kasela, S, De Cesco, S, Wegner, J, Handunnetthi, L, McCann, F, Chen, L, Sekine, T, Brennan, P, Marsden, B, Damerell, D, O’Callaghan, C, Bountra, C, Bowness, P, Sundström, Y, Milani, L, Berg, L, Göhlmann, H, Peeters, P, Fairfax, B, Sundström, M, Knight, J |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
Springer Nature
2019
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease
de réir: Handunnetthi, L, et al.
Foilsithe / Cruthaithe: (2021) -
High-throughput structural characterisation of therapeutic protein targets.
de réir: Marsden, B, et al.
Foilsithe / Cruthaithe: (2006) -
High-throughput structural characterisation of therapeutic protein targets
de réir: Marsden, B, et al.
Foilsithe / Cruthaithe: (2006) -
Insights for the development of specific kinase inhibitors by targeted structural genomics.
de réir: Fedorov, O, et al.
Foilsithe / Cruthaithe: (2007) -
Science Forum: Donated chemical probes for open science
de réir: Müller, S, et al.
Foilsithe / Cruthaithe: (2018)